topiramate

(redirected from Trokendi XR)
Also found in: Medical.
Translations

topiramate

n topiramato
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy.
The analyst continues to caution against drawing parallels between the Oxtellar XR monotherapy opportunity and Trokendi XR in migraine prophylaxis.
Its top products include Trokendi XR, which treats migraines and epilepsy, and Oxtellar XR, which also treats epilepsy.
Cadila, alongside subsidiary Zydus Pharmaceuticals Inc, stated in a BSE filing that it had reached an agreement with Maryland-based Supernus Pharmaceuticals to resolve all outstanding patent litigation in relation to Trokendi XR (topiramate).
This edition has updates to antipsychotic dosages; restructured information on antipsychotic-induced extrapyramidal side effects and their management; more on dosing recommendations for patients with renal or hepatic impairment; pharmacogenomics information for dementia drugs; new drugs and preparations, such as Forfivo, Gralise, Horizant, and Trokendi XR; more on vilazodone; the addition of synthetic cannabinoids to the drugs of abuse; updates on the psychotropic usage of natural health products; and patient handouts.
Second quarter 2019 product prescriptions for Trokendi XR and Oxtellar XR, as reported by IQVIA, totaled 209,066, a 7.4% increase over the second quarter of 2018.
Piper Jaffray analyst David Amsellem says that while his survey of 25 neurologists did not necessarily suggest that Supernus Pharmaceuticals' (SUPN) migraine prophylaxis treatment Trokendi XR will see pressure due to the availability of Amgen's (AMGN) Aimovig, there were data points that suggest Trokendi's volume growth "could slow meaningfully.
M2 PHARMA-February 9, 2017-Supernus awarded eighth US patent for antiepileptic drug Trokendi XR
M2 PHARMA-January 31, 2017-Supernus expands protection coverage for Trokendi XR via seventh US patent
M2 EQUITYBITES-February 9, 2017-Supernus awarded eighth US patent for antiepileptic drug Trokendi XR
M2 PHARMA-August 23, 2016-Supernus Pharmaceuticals receives tentative US FDA approval for Trokendi XR Supplemental New Drug Application